• Japanese
  • Korean
  • Traditional Chinese
  • Simplified Chinese
Cover Image
Market Research Report

Pharmaceutical Drug Delivery Market by Route (Oral (Tablet), Pulmonary (Nebulizer), Injectable, Ocular (Liquid), Topical (Solid), Implantable (Active), Transmucosal), Application, Patient Care Setting - COVID-1 Impact-Forecast to 2025
Published by MarketsandMarkets Product code 953548
Published Content info 439 Pages
Delivery time: 1-2 business days
Price
Back to Top
Pharmaceutical Drug Delivery Market by Route (Oral (Tablet), Pulmonary (Nebulizer), Injectable, Ocular (Liquid), Topical (Solid), Implantable (Active), Transmucosal), Application, Patient Care Setting - COVID-1 Impact-Forecast to 2025
Published: July 31, 2020 Content info: 439 Pages
Description

Title:
Pharmaceutical Drug Delivery Market
by Route (Oral (Tablet), Pulmonary (Nebulizer), Injectable, Ocular (Liquid), Topical (Solid), Implantable (Active), Transmucosal), Application (Cancer, Diabetes), Patient Care Setting (Hospital)- COVID-1 Impact - Forecast to 2025.

"Rising prevalence for chronic diseases and growth in the biologics market are expected to drive the overall growth of the pharmaceutical drug delivery market."

The global pharmaceutical drug delivery market is projected to reach USD 2,015.3 billion by 2025 from USD 1,430.5 billion in 2020, at a CAGR of 7.1% during the forecast period 2020-2025. Growth in this market is mainly driven by the rising prevalence of chronic diseases, growth in the biologics market, and technological advancements and new product launches. On the other hand, the risk of needlestick injuries and the increasing pricing pressure are expected to challenge market growth in the coming years.

"The home care settings segment is expected to grow at the highest CAGR during the forecast period."

Based on facility of use, the pharmaceutical drug delivery market is segmented hospitals, ambulatory surgical centers (ASCs)/clinics, diagnostic centers, home care settings, and other facilities of use. The home care settings segment is expected to grow at a higher CAGR during the forecast period. This can majorly be attributed to increasing use of various drug delivery devices such as injectables, nebulizers, and inhalers in home care settings.

"The conventional injection devices segment accounted for the largest share of the injectable drug delivery market in 2019."

Based on type, the injectable drug delivery technology is segmented into conventional injection devices, self-injection devices, and other devices. In 2019, conventional injection devices accounted for the largest share of the injectable drug delivery technology market. The large share of this segment can primarily be attributed to factors such as the low cost of devices and manufacturing, large molecular size of biologics administered through injectables, and the widespread popularity of conventional devices.

"North America to dominate the market during the forecast period."

In 2019, North America accounted for the largest share of the pharmaceutical drug delivery market. The large share of the North American market is due to factors such as the rising prevalence of chronic diseases such as cancer, respiratory allergies, and diabetes; growth in biologics in the pharmaceuticals market; and the presence of a large number of prominent players in this region.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 (55%), Tier 2 (25%), and Tier 3 (20%)
  • By Designation: C-level (43%), D-level (32%), and Others (25%)
  • By Region: North America (38%), Europe (23%), Asia (29%), and RoW (10%)

List of Companies Profiled in the Report:

  • Johnson & Johnson, Inc. (US)
  • F. Hoffman-La Roche (Switzerland)
  • Merck & Co., Inc. (US)
  • Bayer AG (Germany)
  • Pfizer, Inc. (US)
  • Novartis AG (Switzerland)
  • 3M Company (US)
  • Becton, Dickinson and Company (US)
  • GlaxoSmithKline plc, (UK)
  • Sanofi (France)
  • Antares Pharma, Inc. (US)
  • AbbVie (US)
  • Amgen (US)
  • Boehringer Ingelheim (Germany)
  • AstraZeneca (UK)
  • Eli Lilly and Company (US)
  • Gilead Sciences, Inc. (US)
  • Teva Pharmaceuticals (Israel)
  • Bristol-Myers Squibb (US)
  • Genmab A/S (Denmark)

Research Coverage:

This report provides a detailed picture of the global pharmaceutical drug delivery market. It aims at estimating the size and future growth potential of the market across different segments, such as route of administration, application, facility of use, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Reasons to Buy the Report:

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the pharmaceutical drug delivery market. The report analyzes this market by type, application, route of administration, end user, and region
  • Market Development: Comprehensive information on the lucrative emerging markets, by application, end user, and region
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the pharmaceutical drug delivery market
  • Competitive Assessment: In-depth assessment of growth strategies, product offerings, and capabilities of the leading players in the pharmaceutical drug delivery market
Table of Contents
Product Code: MD 3871

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION AND SCOPE
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 DRUG DELIVERY TECHNOLOGY MARKET SEGMENTATION
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 DRUG DELIVERY TECHNOLOGY MARKET: RESEARCH METHODOLOGY
    • FIGURE 3 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Key industry insights
  • 2.2 MARKET SIZING & VALIDATION APPROACH
  • 2.3 MARKET SIZE ESTIMATION
    • FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
    • FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
    • 2.3.1 MARKET DATA VALIDATION AND TRIANGULATION
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

    • FIGURE 8 DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020 VS. 2025 (USD BILLION)
    • FIGURE 9 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2020 VS. 2025 (USD BILLION)
    • FIGURE 10 DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020 VS. 2025 (USD BILLION)
    • FIGURE 11 DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2020 VS. 2025 (USD BILLION)
    • FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE DRUG DELIVERY TECHNOLOGY MARKET

4 PREMIUM INSIGHTS

  • 4.1 DRUG DELIVERY TECHNOLOGY MARKET OVERVIEW
    • FIGURE 13 RISING PREVALENCE OF CHRONIC DISEASES IS DRIVING THE GROWTH OF THE DRUG DELIVERY TECHNOLOGY MARKET
  • 4.2 DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020 VS. 2025 (USD BILLION)
    • FIGURE 14 TOPICAL DRUG DELIVERY SEGMENT TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • 4.3 DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020-2025 (USD BILLION)
    • FIGURE 15 HOME CARE SETTINGS ARE THE FASTEST-GROWING END USERS OF DRUG DELIVERY TECHNOLOGIES
  • 4.4 DRUG DELIVERY TECHNOLOGY MARKET SHARE, BY APPLICATION AND REGION, 2019
    • FIGURE 16 INFECTIOUS DISEASES SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2019
  • 4.5 DRUG DELIVERY TECHNOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 17 CHINA IS EXPECTED TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 18 DRUG DELIVERY TECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 5.3 DRIVERS
    • 5.3.1 RISING PREVALENCE OF CHRONIC DISEASES
    • 5.3.2 GROWTH IN THE BIOLOGICS MARKET
    • TABLE 1 INDICATIVE LIST OF BIOLOGICS APPROVED BY THE FDA (2020)
    • 5.3.3 TECHNOLOGICAL ADVANCEMENTS AND NEW PRODUCT LAUNCHES
  • 5.4 RESTRAINTS
    • 5.4.1 RISK OF NEEDLESTICK INJURIES
  • 5.5 OPPORTUNITIES
    • 5.5.1 SELF-ADMINISTRATION AND HOME CARE
    • 5.5.2 RISING DEMAND FOR BIOSIMILARS
  • 5.6 CHALLENGES
    • 5.6.1 PRICING PRESSURE
  • 5.7 COVID-19 IMPACT ON THE DRUG DELIVERY TECHNOLOGY MARKET
    • FIGURE 19 IMPACT OF COVID-19 ON THE DRUG DELIVERY TECHNOLOGY MARKET

6 DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1 INTRODUCTION
    • FIGURE 20 TOPICAL DRUG DELIVERY SEGMENT TO REGISTER THE HIGHEST GROWTH IN THE DRUG DELIVERY TECHNOLOGY MARKET FROM 2020 TO 2025
    • TABLE 2 DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016-2019 (USD BILLION)
    • TABLE 3 DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2025 (USD BILLION)
  • 6.2 ORAL DRUG DELIVERY
    • TABLE 4 ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2019 (USD BILLION)
    • TABLE 5 ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020-2025 (USD BILLION)
    • TABLE 6 ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016-2019 (USD BILLION)
    • TABLE 7 ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2020-2025 (USD BILLION)
    • 6.2.1 SOLID ORAL DRUGS
    • TABLE 8 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2016-2019 (USD BILLION
    • TABLE 9 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2020-2025 (USD BILLION)
    • TABLE 10 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 11 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY REGION, 2020-2025 (USD BILLION)
      • 6.2.1.1 Tablets
        • 6.2.1.1.1 Development of mini-tablets is a key trend in this market segment
    • TABLE 12 TABLETS MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 13 TABLETS MARKET, BY REGION, 2020-2025 (USD BILLION)
      • 6.2.1.2 Capsules
        • 6.2.1.2.1 Easy absorption of drugs and decreased irritation in the GI tract are driving the use of capsules
    • TABLE 14 CAPSULES MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 15 CAPSULES MARKET, BY REGION, 2020-2025 (USD BILLION)
      • 6.2.1.3 Powders
        • 6.2.1.3.1 Powders are taken by patients who are unable to swallow oral dosage forms
    • TABLE 16 POWDERS MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 17 POWDERS MARKET, BY REGION, 2020-2025 (USD BILLION)
      • 6.2.1.4 Pills
        • 6.2.1.4.1 Rising incidence of target ailments will propel the growth of the pills market
    • TABLE 18 PILLS MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 19 PILLS MARKET, BY REGION, 2020-2025 (USD BILLION)
    • 6.2.2 LIQUID ORAL DRUGS
    • TABLE 20 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
    • TABLE 21 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2020-2025 (USD BILLION)
    • TABLE 22 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 23 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY REGION, 2020-2025 (USD BILLION)
      • 6.2.2.1 Syrups
        • 6.2.2.1.1 Liquid syrups can be easily administered to patients with swallowing difficulties
    • TABLE 24 ORAL SYRUPS MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 25 ORAL SYRUPS MARKET, BY REGION, 2020-2025 (USD BILLION)
      • 6.2.2.2 Solutions
        • 6.2.2.2.1 Solutions are generally preferred by geriatric and pediatric patients
    • TABLE 26 ORAL SOLUTIONS MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 27 ORAL SOLUTIONS MARKET, BY REGION, 2020-2025 (USD BILLION)
    • 6.2.3 SEMI-SOLID ORAL DRUGS
    • TABLE 28 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
    • TABLE 29 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2020-2025 (USD BILLION)
    • TABLE 30 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 31 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY REGION, 2020-2025 (USD BILLION)
      • 6.2.3.1 Gels
        • 6.2.3.1.1 Gels are used for controlled drug release
    • TABLE 32 ORAL GELS MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 33 ORAL GELS MARKET, BY REGION, 2020-2025 (USD BILLION)
      • 6.2.3.2 Emulsions
        • 6.2.3.2.1 Microemulsions offer protection against oxidation and enzymatic hydrolysis
    • TABLE 34 ORAL EMULSIONS MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 35 ORAL EMULSIONS MARKET, BY REGION, 2020-2025 (USD BILLION)
      • 6.2.3.3 Elixirs
        • 6.2.3.3.1 Elixirs are hydraulic in nature and contain sweet and flavored substances
    • TABLE 36 ELIXIRS MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 37 ELIXIRS MARKET, BY REGION, 2020-2025 (USD MILLION)
  • 6.3 INJECTABLE DRUG DELIVERY
    • TABLE 38 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2019 (USD BILLION)
    • TABLE 39 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020-2025 (USD BILLION)
    • TABLE 40 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 41 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020-2025 (USD BILLION)
    • 6.3.1 CONVENTIONAL INJECTION DEVICES
    • TABLE 42 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 43 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY REGION, 2020-2025 (USD BILLION)
      • 6.3.1.1 By material
    • TABLE 44 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2016-2019 (USD BILLION)
    • TABLE 45 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2020-2025 (USD BILLION)
        • 6.3.1.1.1 Glass
        • 6.3.1.1.1.1 Glass syringes are considered to be one of the most durable and safe materials to store biologic drugs
    • TABLE 46 GLASS SYRINGES MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 47 GLASS SYRINGES MARKET, BY REGION, 2020-2025 (USD BILLION)
        • 6.3.1.1.2 Plastic
        • 6.3.1.1.2.1 Plastic syringes are reasonably priced as compared to their glass counterparts
    • TABLE 48 PLASTIC SYRINGES MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 49 PLASTIC SYRINGES MARKET, BY REGION, 2020-2025 (USD BILLION)
      • 6.3.1.2 By product
    • TABLE 50 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2016-2019 (USD BILLION)
    • TABLE 51 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2020-2025 (USD BILLION)
        • 6.3.1.2.1 Fillable syringes
        • 6.3.1.2.1.1 Ease of use and variable dosing formulations of fillable syringes are the major factors driving market growth
    • TABLE 52 FILLABLE SYRINGES MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 53 FILLABLE SYRINGES MARKET, BY REGION, 2020-2025 (USD BILLION)
        • 6.3.1.2.2 Prefilled syringes
        • 6.3.1.2.2.1 Prefilled syringes offer improved dose accuracy and increased patient convenience and safety
    • TABLE 54 PREFILLED SYRINGES MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 55 PREFILLED SYRINGES MARKET, BY REGION, 2020-2025 (USD BILLION)
      • 6.3.1.3 By usability
    • TABLE 56 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2016-2019 (USD BILLION)
    • TABLE 57 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2020-2025 (USD BILLION)
        • 6.3.1.3.1 Reusable syringes
        • 6.3.1.3.1.1 Reusable syringes are easy to dismantle and clean
    • TABLE 58 REUSABLE SYRINGES MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 59 REUSABLE SYRINGES MARKET, BY REGION, 2020-2025 (USD BILLION)
        • 6.3.1.3.2 Disposable syringes
        • 6.3.1.3.2.1 Disposable syringes are widely used in medical practices due to their low cost and convenience
    • TABLE 60 DISPOSABLE SYRINGES MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 61 DISPOSABLE SYRINGES MARKET, BY REGION, 2020-2025 (USD BILLION)
    • 6.3.2 SELF-INJECTION DEVICES
    • TABLE 62 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 63 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2020-2025 (USD BILLION)
    • TABLE 64 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 65 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY REGION, 2020-2025 (USD BILLION)
      • 6.3.2.1 Needle-free injectors
        • 6.3.2.1.1 Needle-free injectors enable fast drug delivery and show better reproducibility as compared to invasive drug delivery systems
    • TABLE 66 NEEDLE-FREE INJECTORS MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 67 NEEDLE-FREE INJECTORS MARKET, BY REGION, 2020-2025 (USD BILLION)
      • 6.3.2.2 Autoinjectors
        • 6.3.2.2.1 Autoinjectors provide improved patient satisfaction as compared to manual injections
    • TABLE 68 AUTOINJECTORS MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 69 AUTOINJECTORS MARKET, BY REGION, 2020-2025 (USD BILLION)
      • 6.3.2.3 Pen injectors
        • 6.3.2.3.1 Pen injectors are generally used when medications have to be administered more than once a week
    • TABLE 70 COMMERCIALLY AVAILABLE KEY PEN INJECTORS
    • TABLE 71 PEN INJECTORS MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 72 PEN INJECTORS MARKET, BY REGION, 2020-2025 (USD BILLION)
      • 6.3.2.4 Wearable injectors
        • 6.3.2.4.1 Increasing adoption of home infusion therapy and rising focus on cost-curtailment in healthcare are supporting market growth
    • TABLE 73 WEARABLE INJECTORS MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 74 WEARABLE INJECTORS MARKET, BY REGION, 2020-2025 (USD MILLION)
    • 6.3.3 OTHER INJECTOR DEVICES
    • TABLE 75 OTHER INJECTOR DEVICES MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 76 OTHER INJECTOR DEVICES MARKET, BY REGION, 2020-2025 (USD BILLION)
  • 6.4 TOPICAL DRUG DELIVERY
    • TABLE 77 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2019 (USD BILLION)
    • TABLE 78 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020-2025 (USD BILLION)
    • TABLE 79 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 80 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020-2025 (USD BILLION)
    • 6.4.1 LIQUID FORMULATIONS
    • TABLE 81 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
    • TABLE 82 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2020-2025 (USD BILLION)
    • TABLE 83 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 84 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY REGION, 2020-2025 (USD BILLION)
      • 6.4.1.1 Solutions
        • 6.4.1.1.1 Solutions accounted for a larger share of the topical drug delivery technology market for liquid formulations in 2018
    • TABLE 85 TOPICAL SOLUTIONS MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 86 TOPICAL SOLUTIONS MARKET, BY REGION, 2020-2025 (USD BILLION)
      • 6.4.1.2 Suspensions
        • 6.4.1.2.1 Factors such as higher rate of bioavailability and the controlled onset of action to support the growth of the topical suspensions market in the coming years
    • TABLE 87 TOPICAL SUSPENSIONS MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 88 TOPICAL SUSPENSIONS MARKET, BY REGION, 2020-2025 (USD BILLION)
    • 6.4.2 SEMI-SOLID FORMULATIONS
    • TABLE 89 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
    • TABLE 90 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2020-2025 (USD BILLION)
    • TABLE 91 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 92 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY REGION, 2020-2025 (USD BILLION)
      • 6.4.2.1 Creams
        • 6.4.2.1.1 Creams are either water-in-oil or oil-in-water emulsions
    • TABLE 93 TOPICAL CREAMS MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 94 TOPICAL CREAMS MARKET, BY REGION, 2020-2025 (USD BILLION)
      • 6.4.2.2 Gels
        • 6.4.2.2.1 Faster drug release and greater patient acceptability are the key factors driving the market for topical gels
    • TABLE 95 TOPICAL GELS MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 96 TOPICAL GELS MARKET, BY REGION, 2020-2025 (USD MILLION)
      • 6.4.2.3 Ointments
        • 6.4.2.3.1 Ointments are widely used in analgesic indications
    • TABLE 97 TOPICAL OINTMENTS MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 98 TOPICAL OINTMENTS MARKET, BY REGION, 2020-2025 (USD BILLION)
      • 6.4.2.4 Pastes
        • 6.4.2.4.1 Topical pastes are widely used for the treatment and prevention of skin irritation
    • TABLE 99 TOPICAL PASTES MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 100 TOPICAL PASTES MARKET, BY REGION, 2020-2025 (USD MILLION)
      • 6.4.2.5 Lotions
        • 6.4.2.5.1 Easy administration of lotions to drive their demand among end users
    • TABLE 101 TOPICAL LOTIONS MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 102 TOPICAL LOTIONS MARKET, BY REGION, 2020-2025 (USD BILLION)
    • 6.4.3 SOLID FORMULATIONS
    • TABLE 103 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2019 (USD MILLION)
    • TABLE 104 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2020-2025 (USD MILLION)
    • TABLE 105 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 106 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY REGION, 2020-2025 (USD MILLION)
      • 6.4.3.1 Suppositories
        • 6.4.3.1.1 Suppositories require a suitable base that ensures the compatibility and stability of the drug
    • TABLE 107 TOPICAL SUPPOSITORIES MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 108 TOPICAL SUPPOSITORIES MARKET, BY REGION, 2020-2025 (USD MILLION)
      • 6.4.3.2 Powders
        • 6.4.3.2.1 Powders have a very fine particle size that covers a large surface area per unit weight
    • TABLE 109 TOPICAL POWDERS MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 110 TOPICAL POWDERS MARKET, BY REGION, 2020-2025 (USD BILLION)
    • 6.4.4 TRANSDERMAL PRODUCTS
    • TABLE 111 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 112 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020-2025 (USD BILLION)
    • TABLE 113 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 114 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY REGION, 2020-2025 (USD BILLION)
      • 6.4.4.1 Transdermal patches
        • 6.4.4.1.1 Transdermal patches prevent the premature metabolization of the drug through the liver
    • TABLE 115 TRANSDERMAL PATCHES MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 116 TRANSDERMAL PATCHES MARKET, BY REGION, 2020-2025 (USD MILLION)
      • 6.4.4.2 Transdermal gels
        • 6.4.4.2.1 Transdermal gels help in the faster release of drugs on the target site
    • TABLE 117 TRANSDERMAL GELS MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 118 TRANSDERMAL GELS MARKET, BY REGION, 2020-2025 (USD MILLION)
  • 6.5 OCULAR DRUG DELIVERY
    • TABLE 119 OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2019 (USD BILLION)
    • TABLE 120 OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020-2025 (USD BILLION)
    • TABLE 121 OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 122 OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020-2025 (USD BILLION)
    • 6.5.1 LIQUID FORMULATIONS
    • TABLE 123 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
    • TABLE 124 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2020-2025 (USD BILLION)
    • TABLE 125 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 126 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY REGION, 2020-2025 (USD BILLION)
      • 6.5.1.1 Eye drops
        • 6.5.1.1.1 Rising prevalence of cataracts and other eye diseases is driving market growth
    • TABLE 127 COMMERCIALLY AVAILABLE EYE DROPS
    • TABLE 128 EYE DROPS MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 129 EYE DROPS MARKET, BY REGION, 2020-2025 (USD BILLION)
      • 6.5.1.2 Liquid sprays
        • 6.5.1.2.1 Liquid sprays have helped in overcoming drawbacks associated with traditional eye drops
    • TABLE 130 LIQUID SPRAYS MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 131 LIQUID SPRAYS MARKET, BY REGION, 2020-2025 (USD BILLION)
    • 6.5.2 SEMI-SOLID FORMULATIONS
    • TABLE 132 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2019 (USD MILLION)
    • TABLE 133 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2020-2025 (USD MILLION)
    • TABLE 134 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 135 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY REGION, 2020-2025 (USD MILLION)
      • 6.5.2.1 Gels
        • 6.5.2.1.1 High viscosity of drugs, prolonged drug release, and ease of drug administration are factors contributing to market growth
    • TABLE 136 OCULAR GELS MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 137 OCULAR GELS MARKET, BY REGION, 2020-2025 (USD MILLION)
      • 6.5.2.2 Eye ointments
        • 6.5.2.2.1 Eye ointments are safe to use, and help in improving ocular contact time with the drug
    • TABLE 138 EYE OINTMENTS MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 139 EYE OINTMENTS MARKET, BY REGION, 2020-2025 (USD MILLION)
    • 6.5.3 OCULAR DEVICES
    • TABLE 140 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 141 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 142 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 143 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY REGION, 2020-2025 (USD MILLION)
      • 6.5.3.1 Drug-coated contact lenses
        • 6.5.3.1.1 Better eyesight offered by lenses & high compliance to drive the market for drug-coated contact lenses
    • TABLE 144 DRUG-COATED CONTACT LENSES MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 145 DRUG-COATED CONTACT LENSES MARKET, BY REGION, 2020-2025 (USD MILLION)
      • 6.5.3.2 Ocular inserts
        • 6.5.3.2.1 Ocular inserts help in the sustained release of drugs in the eye
    • TABLE 146 OCULAR INSERTS MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 147 OCULAR INSERTS MARKET, BY REGION, 2020-2025 (USD MILLION)
  • 6.6 PULMONARY DRUG DELIVERY
    • TABLE 148 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2019 (USD BILLION)
    • TABLE 149 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020-2025 (USD BILLION)
    • TABLE 150 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 151 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020-2025 (USD BILLION)
    • 6.6.1 METERED-DOSE INHALERS
      • 6.6.1.1 These inhalers overcome the problem of poor coordination between inhaler actuation and patient breath
    • TABLE 152 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR METERED-DOSE INHALERS, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 153 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR METERED-DOSE INHALERS, BY REGION, 2020-2025 (USD BILLION)
    • 6.6.2 DRY POWDER INHALERS
      • 6.6.2.1 DPI drug formulations are chemically more stable than their counterparts
    • TABLE 154 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR DRY POWDER INHALERS, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 155 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR DRY POWDER INHALERS, BY REGION, 2020-2025 (USD BILLION)
    • 6.6.3 NEBULIZERS
    • TABLE 156 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 157 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2020-2025 (USD BILLION)
    • TABLE 158 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 159 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY REGION, 2020-2025 (USD BILLION)
      • 6.6.3.1 Jet nebulizers
        • 6.6.3.1.1 Jet nebulizers account for the largest share of the nebulizers market
    • TABLE 160 JET NEBULIZERS MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 161 JET NEBULIZERS MARKET, BY REGION, 2020-2025 (USD MILLION)
      • 6.6.3.2 Ultrasonic nebulizers
        • 6.6.3.2.1 Ultrasonic nebulizers are easy to use and comfortable to handle
    • TABLE 162 ULTRASONIC NEBULIZERS MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 163 ULTRASONIC NEBULIZERS MARKET, BY REGION, 2020-2025 (USD MILLION)
      • 6.6.3.3 Soft mist nebulizers
        • 6.6.3.3.1 Soft mist nebulizers are preferred for the treatment of severe COPD
    • TABLE 164 SOFT MIST NEBULIZERS MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 165 SOFT MIST NEBULIZERS MARKET, BY REGION, 2020-2025 (USD MILLION)
  • 6.7 NASAL DRUG DELIVERY
    • TABLE 166 NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2019 (USD BILLION)
    • TABLE 167 NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020-2025 (USD BILLION)
    • TABLE 168 NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016-2019 (USD BILLION)
    • TABLE 169 NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2020-2025 (USD BILLION)
    • 6.7.1 NASAL DROPS
      • 6.7.1.1 Nasal drops are considered more efficient than nasal sprays
    • TABLE 170 NASAL DROPS MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 171 NASAL DROPS MARKET, BY REGION, 2020-2025 (USD BILLION)
    • 6.7.2 NASAL SPRAYS
      • 6.7.2.1 Nasal sprays help in relieving nasal congestion, runny nose, itchy nose, and sneezing
    • TABLE 172 NASAL SPRAYS MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 173 NASAL SPRAYS MARKET, BY REGION, 2020-2025 (USD BILLION)
    • 6.7.3 NASAL POWDERS
      • 6.7.3.1 Absence of preservatives & superior stability of formulations are some of the advantages associated with nasal powders
    • TABLE 174 NASAL POWDERS MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 175 NASAL POWDERS MARKET, BY REGION, 2020-2025 (USD MILLION)
    • 6.7.4 NASAL GELS
      • 6.7.4.1 Nasal gels provide long-lasting relief from dry nasal passages and also reduce irritation caused by using soothing excipients
    • TABLE 176 NASAL GELS MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 177 NASAL GELS MARKET, BY REGION, 2020-2025 (USD MILLION)
  • 6.8 TRANSMUCOSAL DRUG DELIVERY
    • TABLE 178 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2019 (USD BILLION)
    • TABLE 179 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020-2025 (USD BILLION)
    • TABLE 180 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 181 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020-2025 (USD BILLION)
    • 6.8.1 ORAL FORMULATIONS
    • TABLE 182 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 183 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2020-2025 (USD BILLION)
    • TABLE 184 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 185 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY REGION, 2020-2025 (USD BILLION)
      • 6.8.1.1 Buccal drug delivery
        • 6.8.1.1.1 Buccal drug delivery system is suitable for local and systematic therapies
    • TABLE 186 BUCCAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 187 BUCCAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2020-2025 (USD BILLION)
      • 6.8.1.2 Sublingual drug delivery
        • 6.8.1.2.1 The rate of drug absorption through the sublingual route is 3-10 times higher than the oral route
    • TABLE 188 SUBLINGUAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 189 SUBLINGUAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2020-2025 (USD BILLION)
    • 6.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES
    • TABLE 190 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 191 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 192 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 193 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY REGION, 2020-2025 (USD MILLION)
      • 6.8.2.1 Rectal transmucosal drug delivery
        • 6.8.2.1.1 The rectal route of drug delivery rapidly absorbs drugs that are aqueous in nature
    • TABLE 194 RECTAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 195 RECTAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2020-2025 (USD MILLION)
      • 6.8.2.2 Vaginal transmucosal drug delivery
        • 6.8.2.2.1 The permeability of the drug is high through the vaginal route of administration
    • TABLE 196 VAGINAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 197 VAGINAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2020-2025 (USD MILLION)
  • 6.9 IMPLANTABLE DRUG DELIVERY
    • TABLE 198 IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2019 (USD BILLION)
    • TABLE 199 IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020-2025 (USD BILLION)
    • TABLE 200 IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 201 IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • 6.9.1 ACTIVE IMPLANTABLE DRUG DELIVERY
      • 6.9.1.1 Active implantable devices are used for diagnostic monitoring, body fluids transportation, and ionized radiation
    • TABLE 202 ACTIVE IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 203 ACTIVE IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2020-2025 (USD MILLION)
    • 6.9.2 PASSIVE IMPLANTABLE DRUG DELIVERY
      • 6.9.2.1 Passive implants primarily include joint replacements, heart valves, aneurysm clips, coronary stents, and breast implants
    • TABLE 204 PASSIVE IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 205 PASSIVE IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2020-2025 (USD MILLION)

7 DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE

  • 7.1 INTRODUCTION
    • FIGURE 21 HOME CARE SETTINGS TO WITNESS THE HIGHEST GROWTH IN THE DRUG DELIVERY TECHNOLOGY MARKET FROM 2020 TO 2025
    • TABLE 206 DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016-2019 (USD BILLION)
    • TABLE 207 DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020-2025 (USD BILLION)
  • 7.2 HOSPITALS
    • 7.2.1 HOSPITALS WILL CONTINUE TO DOMINATE THE DRUG DELIVERY TECHNOLOGY MARKET DURING THE FORECAST PERIOD
    • TABLE 208 DRUG DELIVERY TECHNOLOGY MARKET FOR HOSPITALS, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 209 DRUG DELIVERY TECHNOLOGY MARKET FOR HOSPITALS, BY REGION, 2020-2025 (USD BILLION)
  • 7.3 AMBULATORY SURGERY CENTERS/CLINICS
    • 7.3.1 INCREASING PREFERENCE FOR ASCS HAS RESULTED IN A SIGNIFICANT RISE IN DEMAND FOR DRUG DELIVERY TECHNOLOGIES
    • TABLE 210 DRUG DELIVERY TECHNOLOGY MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 211 DRUG DELIVERY TECHNOLOGY MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY REGION, 2020-2025 (USD BILLION)
  • 7.4 HOME CARE SETTINGS
    • 7.4.1 HOME CARE SETTINGS TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
    • TABLE 212 DRUG DELIVERY TECHNOLOGY MARKET FOR HOME CARE SETTINGS, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 213 DRUG DELIVERY TECHNOLOGY MARKET FOR HOME CARE SETTINGS, BY REGION, 2020-2025 (USD BILLION)
  • 7.5 DIAGNOSTIC CENTERS
    • 7.5.1 RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH
    • TABLE 214 DRUG DELIVERY TECHNOLOGY MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 215 DRUG DELIVERY TECHNOLOGY MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2020-2025 (USD BILLION)
  • 7.6 OTHER FACILITIES OF USE
    • TABLE 216 DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FACILITIES OF USE, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 217 DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FACILITIES OF USE, BY REGION, 2020-2025 (USD BILLION)

8 DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 COVID-19 IMPACT, BY APPLICATION
    • FIGURE 22 INFECTIOUS DISEASES SEGMENT WILL DOMINATE THE DRUG DELIVERY TECHNOLOGY MARKET DURING THE FORECAST PERIOD
    • TABLE 218 DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2016-2019 (USD BILLION)
    • TABLE 219 DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2020-2025 (USD BILLION)
  • 8.3 INFECTIOUS DISEASES
    • 8.3.1 HIGH BURDEN OF INFECTIOUS DISEASES ACROSS THE GLOBE TO DRIVE MARKET GROWTH
    • TABLE 220 DRUG DELIVERY TECHNOLOGY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 221 DRUG DELIVERY TECHNOLOGY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020-2025 (USD BILLION)
  • 8.4 CANCER
    • 8.4.1 CANCER FORMS A KEY THERAPEUTIC APPLICATION SEGMENT FOR DRUG DELIVERY TECHNOLOGIES
    • TABLE 222 DRUG DELIVERY TECHNOLOGY MARKET FOR CANCER, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 223 DRUG DELIVERY TECHNOLOGY MARKET FOR CANCER, BY REGION, 2020-2025 (USD BILLION)
  • 8.5 CARDIOVASCULAR DISEASES
    • 8.5.1 INCREASING PREVALENCE OF CVD IS DRIVING THE GROWTH OF THE DRUG DELIVERY TECHNOLOGY MARKET
    • TABLE 224 DRUG DELIVERY TECHNOLOGY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 225 DRUG DELIVERY TECHNOLOGY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020-2025 (USD BILLION) 199
  • 8.6 DIABETES
    • 8.6.1 EMERGENCE OF NEW TECHNOLOGIES IS SUPPORTING MARKET GROWTH
    • TABLE 226 DRUG DELIVERY TECHNOLOGY MARKET FOR DIABETES, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 227 DRUG DELIVERY TECHNOLOGY MARKET FOR DIABETES, BY REGION, 2020-2025 (USD BILLION)
  • 8.7 RESPIRATORY DISEASES
    • 8.7.1 HIGH PREVALENCE OF ASTHMA & COPD TO DRIVE THE ADOPTION OF DRUG DELIVERY TECHNOLOGIES
    • TABLE 228 DRUG DELIVERY TECHNOLOGY MARKET FOR RESPIRATORY DISEASES, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 229 DRUG DELIVERY TECHNOLOGY MARKET FOR RESPIRATORY DISEASES, BY REGION, 2020-2025 (USD BILLION)
  • 8.8 CENTRAL NERVOUS SYSTEM DISORDERS
    • 8.8.1 ORAL AND INJECTABLE DRUG DELIVERY SYSTEMS ARE WIDELY USED IN THE TREATMENT OF CNS DISORDERS
    • TABLE 230 DRUG DELIVERY TECHNOLOGY MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 231 DRUG DELIVERY TECHNOLOGY MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2020-2025 (USD BILLION)
  • 8.9 AUTOIMMUNE DISEASES
    • 8.9.1 AUTOIMMUNE DISEASES SEGMENT TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD
    • TABLE 232 DRUG DELIVERY TECHNOLOGY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 233 DRUG DELIVERY TECHNOLOGY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2020-2025 (USD BILLION)
  • 8.10 OTHER APPLICATIONS
    • 8.10.1 OPHTHALMIC DISORDERS
    • 8.10.2 ENDOCRINE DISORDERS
    • TABLE 234 DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER APPLICATIONS, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 235 DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020-2025 (USD BILLION)

9 DRUG DELIVERY TECHNOLOGY MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 236 DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016-2019 (USD BILLION)
    • TABLE 237 DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2020-2025 (USD BILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 23 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT
    • TABLE 238 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2019 (USD BILLION)
    • TABLE 239 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020-2025 (USD BILLION)
    • TABLE 240 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016-2019 (USD BILLION)
    • TABLE 241 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2025 (USD BILLION)
    • TABLE 242 NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 243 NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020-2025 (USD BILLION)
    • TABLE 244 NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
    • TABLE 245 NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2020-2025 (USD BILLION)
    • TABLE 246 NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
    • TABLE 247 NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2020-2025 (USD BILLION)
    • TABLE 248 NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
    • TABLE 249 NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2020-2025 (USD BILLION)
    • TABLE 250 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 251 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020-2025 (USD BILLION)
    • TABLE 252 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2016-2019 (USD BILLION)
    • TABLE 253 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2020-2025 (USD BILLION)
    • TABLE 254 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2016-2019 (USD BILLION)
    • TABLE 255 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2020-2025 (USD BILLION)
    • TABLE 256 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2016-2019 (USD BILLION)
    • TABLE 257 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2020-2025 (USD BILLION)
    • TABLE 258 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 259 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2020-2025 (USD BILLION)
    • TABLE 260 NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 261 NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020-2025 (USD BILLION)
    • TABLE 262 NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
    • TABLE 263 NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2020-2025 (USD BILLION)
    • TABLE 264 NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2019 (USD MILLION)
    • TABLE 265 NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2020-2025 (USD MILLION)
    • TABLE 266 NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 267 NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 268 NORTH AMERICA: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016-2019 (USD MILLION)
    • TABLE 269 NORTH AMERICA: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2020-2025 (USD MILLION)
    • TABLE 270 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 271 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020-2025 (USD BILLION)
    • TABLE 272 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
    • TABLE 273 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2020-2025 (USD BILLION)
    • TABLE 274 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2019 (USD MILLION)
    • TABLE 275 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2020-2025 (USD MILLION)
    • TABLE 276 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2019 (USD MILLION)
    • TABLE 277 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2020-2025 (USD MILLION)
    • TABLE 278 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 279 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 280 NORTH AMERICA: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 281 NORTH AMERICA: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 282 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 283 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 284 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 285 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2020-2025 (USD BILLION)
    • TABLE 286 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 287 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 288 NORTH AMERICA: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 289 NORTH AMERICA: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020-2025 (USD BILLION)
    • TABLE 290 NORTH AMERICA: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 291 NORTH AMERICA: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 292 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2016-2019 (USD BILLION)
    • TABLE 293 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2020-2025 (USD BILLION)
    • TABLE 294 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016-2019 (USD BILLION)
    • TABLE 295 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020-2025 (USD BILLION)
    • 9.2.1 US
      • 9.2.1.1 Rising prevalence of chronic diseases and the strong presence of key market players are driving market growth in the US
    • TABLE 296 US: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016-2019 (USD BILLION)
    • TABLE 297 US: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2025 (USD BILLION)
    • TABLE 298 US: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016-2019 (USD BILLION)
    • TABLE 299 US: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020-2025 (USD BILLION)
    • 9.2.2 CANADA
      • 9.2.2.1 Government support for research and the rising prevalence of chronic diseases are driving the market in Canada
    • TABLE 300 CANADA: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016-2019 (USD BILLION)
    • TABLE 301 CANADA: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2025 (USD BILLION)
    • TABLE 302 CANADA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016-2019 (USD BILLION)
    • TABLE 303 CANADA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020-2025 (USD BILLION)
  • 9.3 EUROPE
    • FIGURE 24 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT
    • TABLE 304 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2019 (USD BILLION)
    • TABLE 305 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020-2025 (USD BILLION)
    • TABLE 306 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016-2019 (USD BILLION)
    • TABLE 307 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2025 (USD BILLION)
    • TABLE 308 EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 309 EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020-2025 (USD BILLION)
    • TABLE 310 EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
    • TABLE 311 EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2020-2025 (USD BILLION)
    • TABLE 312 EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
    • TABLE 313 EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2020-2025 (USD BILLION)
    • TABLE 314 EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
    • TABLE 315 EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2020-2025 (USD BILLION)
    • TABLE 316 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 317 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020-2025 (USD BILLION)
    • TABLE 318 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2016-2019 (USD BILLION)
    • TABLE 319 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2020-2025 (USD BILLION)
    • TABLE 320 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2016-2019 (USD BILLION)
    • TABLE 321 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2020-2025 (USD BILLION)
    • TABLE 322 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2016-2019 (USD BILLION)
    • TABLE 323 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2020-2025 (USD BILLION)
    • TABLE 324 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 325 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2020-2025 (USD BILLION)
    • TABLE 326 EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 327 EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020-2025 (USD BILLION)
    • TABLE 328 EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
    • TABLE 329 EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2025-2025 (USD BILLION)
    • TABLE 330 EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
    • TABLE 331 EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2020-2025 (USD BILLION)
    • TABLE 332 EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 333 EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 334 EUROPE: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016-2019 (USD MILLION)
    • TABLE 335 EUROPE: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2020-2025 (USD MILLION)
    • TABLE 336 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 337 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020-2025 (USD BILLION)
    • TABLE 338 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
    • TABLE 339 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2020-2025 (USD BILLION)
    • TABLE 340 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
    • TABLE 341 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2020-2025 (USD BILLION)
    • TABLE 342 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2019 (USD MILLION)
    • TABLE 343 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2020-2025 (USD MILLION)
    • TABLE 344 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 345 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 346 EUROPE: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 347 EUROPE: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 348 EUROPE: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 349 EUROPE: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020-2025 (USD BILLION)
    • TABLE 350 EUROPE: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 351 EUROPE: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2020-2025 (USD BILLION)
    • TABLE 352 EUROPE: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 353 EUROPE: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 354 EUROPE: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD BILLION)
    • TABLE 355 EUROPE: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020-2025 (USD BILLION)
    • TABLE 356 EUROPE: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 357 EUROPE: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 358 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2016-2019 (USD BILLION)
    • TABLE 359 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2020-2025 (USD BILLION)
    • TABLE 360 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016-2019 (USD BILLION)
    • TABLE 361 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020-2025 (USD BILLION) 251
Back to Top

About Contact User Guide Privacy Policy Terms and Conditions Site Map

© Copyright 1997-2020, Global Information, Inc. All rights reserved.